Repatha for ASCVD Secondary Prevention: Insurance and Cost Reality for Women

What Repatha Actually Is and Why Women Need to Know About Insurance Before Starting

Repatha (evolocumab) is a PCSK9 inhibitor. It works by blocking the PCSK9 protein, which normally degrades LDL receptors on liver cells. When PCSK9 is blocked, more LDL receptors stay on the cell surface and pull more LDL-C out of the bloodstream. The result is a roughly 60% additional reduction in LDL-C on top of whatever a statin is already doing.

The FDA approved evolocumab for ASCVD secondary prevention in 2017, based on the FOURIER trial. This is not an off-label use. But approved does not mean automatically covered. Most insurers still require proof that you have tried and failed to reach LDL targets on high-intensity statin therapy before they will authorize a PCSK9 inhibitor. For many women, that process takes months and multiple appeals.

Why Women Are More Likely to Hit Insurance Roadblocks

The insurance problem is not gender-neutral. Several factors converge for women.

First, ASCVD is under-diagnosed in women until it is advanced. Women are more likely to present with atypical symptoms, less likely to receive aggressive lipid-lowering after a cardiac event, and more likely to be classified as "lower risk" on calculators that do not weight female-specific risk factors like premature menopause, preeclampsia history, or PCOS. If your cardiologist or primary care provider has not documented your ASCVD event clearly, prior authorization letters will cite insufficient evidence of clinical necessity.

Second, women in the FOURIER trial made up only about 25% of the enrolled population. Insurers and guidelines draw on that data, but it means the benefit estimates are less precise for women. The absolute risk reduction in women was directionally consistent with men, but the confidence intervals are wider. This does not mean the drug works less well in women; it means fewer women were studied.

Third, postmenopausal women often arrive at ASCVD secondary prevention with a complex lipid picture. Estrogen suppresses PCSK9 expression. When estrogen falls at menopause, PCSK9 activity rises and LDL-C climbs, sometimes by 10-15 mg/dL or more. That shift is not always recognized as a clinical event requiring medication escalation, so some women do not get maximally-titrated statin therapy documented in their chart before they need a PCSK9 inhibitor, which is exactly what insurers check.

The FOURIER Trial: What the Data Actually Show for Women

The FOURIER trial (NCT01764633) enrolled 27,564 patients with established ASCVD who were already on statin therapy. Over a median of 2.2 years, evolocumab at 140 mg every 2 weeks or 420 mg monthly reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% relative risk reduction compared with placebo (9.8% vs 11.3%, HR 0.85, 95% CI 0.79-0.92).

The secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (5.9% vs 7.4%).

What the Women-Specific Subgroup Shows

A pre-specified subgroup analysis of women in FOURIER found directionally consistent benefit, but the trial was not powered to detect statistically significant differences within the female subgroup alone. Sabatine et al. reported no significant interaction by sex (p-interaction = 0.70 for the primary endpoint), meaning the drug appears to work similarly in women and men. But given that only roughly 6,900 women were included, you should know the female-specific evidence is extrapolated rather than independently validated at scale.

Longer-Term Data from the FOURIER Open-Label Extension

The FOURIER-OLE extension followed patients for up to 8.4 years total. Sabatine et al., 2022 found that longer-term evolocumab exposure was associated with a 23% reduction in cardiovascular death, MI, or stroke compared with placebo in the overall cohort. This longer-duration data strengthens the case for sustained PCSK9 inhibition and is useful in appeals that question long-term necessity.

FDA-Approved Indications vs. What Insurers Actually Cover

Evolocumab carries three FDA-approved indications:

1. Primary hyperlipidemia (as an adjunct to diet and maximally tolerated statin therapy)
2. ASCVD secondary prevention to reduce cardiovascular events
3. Homozygous familial hypercholesterolemia (HoFH)

The ASCVD secondary prevention indication is the most commonly sought by women post-heart attack, post-stroke, or post-stent. It is FDA-approved. It is not off-label. The problem is payer policy, not regulatory status.

American College of Cardiology / American Heart Association 2022 cholesterol guidelines recommend PCSK9 inhibitors for very high-risk ASCVD patients when LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy, with or without ezetimibe. "Very high-risk" means a history of multiple major ASCVD events or one major ASCVD event plus multiple high-risk conditions.

If you meet that definition, you have a strong clinical argument for coverage. Document it.

Prior Authorization: The Step-by-Step Reality

Prior authorization (PA) for Repatha is almost universal across commercial plans, Medicare Part D, and Medicaid managed care. The initial denial rate across commercial payers runs estimated at 50-80%, though published figures vary by plan and year.

What Your Provider Needs to Submit

The PA request will need to include:

• Documented ASCVD diagnosis (ICD-10 code: I25.110 for atherosclerotic heart disease with unstable angina, or the specific code for your event)
• Current LDL-C level (most payers require LDL-C at or above 70 mg/dL, sometimes 100 mg/dL)
• Proof of maximally tolerated statin use for at least 4-12 weeks (payer-specific)
• Proof that ezetimibe has been tried (some payers require it; others do not)
• Documented intolerance if statin was not maximally dosed

What Triggers a Denial

The most common denial reasons include: LDL-C below the payer's threshold, no documented statin trial, no documented ezetimibe trial, and missing documentation of ASCVD event. For women, an additional common issue is an event that was coded or recorded in ways that do not clearly establish "established ASCVD" in the payer's algorithm.

The Appeal Process

If denied, your provider can file a peer-to-peer review request. This is a direct physician-to-physician call between your cardiologist and the insurer's medical reviewer. Success rates for peer-to-peer reviews are meaningfully higher than initial PA rates. If peer-to-peer fails, a formal appeal citing ACC/AHA guideline language and the FOURIER trial data is the next step. A second-level appeal, then an external independent review, follows after that.

Some states have external review protections that require independent reviewers to evaluate medical necessity. These are worth knowing about.

Real Cost: What You Will Pay Without Coverage

Repatha's list price is approximately $690 per month for the 140 mg auto-injector (two pens per month) and similar for the 420 mg monthly prefilled cartridge for the SureClick device. Without any discount or assistance, annual cost approaches $8,300.

Amgen's Patient Assistance Programs

Amgen operates two programs relevant to Repatha:

Repatha SupportPlus (commercial insurance): Eligible commercially insured patients may pay as little as $0 per month through a copay card, subject to income and other eligibility criteria. This does not apply to patients on Medicare, Medicaid, or other federal programs.

Amgen Safety Net Foundation: For uninsured or underinsured patients with household incomes at or below 600% of the federal poverty level, free product may be available. The application requires income documentation and a provider signature.

Mark Brager, PharmD, senior director at Amgen patient support programs, has stated in educational forums that the manufacturer's intent is that no eligible patient should pay full list price, though eligibility requirements apply and change annually.

GoodRx and Manufacturer Coupons

GoodRx and similar discount platforms rarely produce meaningful savings on biologics like evolocumab because the drug is not available as a generic. The savings shown on GoodRx for Repatha are typically modest compared with the list price reduction available through Amgen's own program for commercially insured patients.

Medicare Part D Patients

Medicare Part D beneficiaries cannot use manufacturer copay cards. For these patients, the cost picture changed significantly with the Inflation Reduction Act's cap on Part D out-of-pocket spending at $2,000 per year starting in 2025. Before that cap, catastrophic-phase spending on Repatha could be substantial. If you are on Medicare, ask your pharmacist to run a cost comparison across Part D plans during open enrollment, specifically searching for plans with preferred PCSK9 inhibitor placement.

Women-Specific Factors That Change the Clinical Urgency

Postmenopausal Cardiovascular Risk

Before menopause, women have lower rates of ASCVD than age-matched men. After menopause, that gap closes rapidly. The Nurses' Health Study and subsequent prospective data confirm that surgical or premature natural menopause (before age 45) is associated with meaningfully higher ASCVD risk independent of traditional risk factors. Postmenopausal women who have already had a cardiac event are exactly the population where aggressive LDL lowering matters most, yet they are often undertreated relative to men of comparable risk.

If you are postmenopausal and had a coronary event, documenting your hormonal status, menopausal age, and any history of premature menopause strengthens the clinical necessity argument in a PA appeal.

PCOS and Elevated Cardiovascular Risk

Women with polycystic ovary syndrome (PCOS) have higher rates of insulin resistance, elevated LDL-C, and metabolic dysfunction. A 2020 meta-analysis in Fertility and Sterility found that women with PCOS have significantly higher prevalence of dyslipidemia compared with controls. If you have PCOS and an established ASCVD event, your lipid management plan deserves extra attention, and the threshold for escalation to a PCSK9 inhibitor may be reached sooner given the underlying metabolic burden.

Perimenopause: The Lipid Transition Window

During perimenopause, LDL-C can rise by 10-20 mg/dL over 2-4 years as estrogen fluctuates and eventually declines. Women who were previously at LDL goal on a moderate-intensity statin may find themselves above target during this window. This is not treatment failure in the traditional sense; it is a hormonally driven shift. Perimenopause is a life-stage marker worth noting explicitly in your medical record so that medication escalation is framed correctly for insurance purposes.

Pregnancy, Lactation, and Contraception: Required Safety Information

This section is required reading if you are of reproductive age.

Pregnancy

Evolocumab is not recommended during pregnancy. The FDA prescribing information notes that there are no adequate and well-controlled studies in pregnant women. Animal reproductive studies showed no adverse effects on fetal development at doses up to 12 times the maximum recommended human dose, but animal data do not reliably predict human outcomes. Because LDL-C and cholesterol are needed for fetal development, aggressive lipid lowering during pregnancy carries theoretical concerns. Statins are contraindicated in pregnancy. PCSK9 inhibitors should be avoided. If you become pregnant while taking Repatha, stop the drug and contact your provider immediately.

Lactation

It is not known whether evolocumab is present in human breast milk. Monoclonal antibodies are generally transferred into breast milk at low levels, but gastrointestinal absorption by the nursing infant is likely minimal given the size of the molecule. The FDA label recommends considering the developmental and health benefits of breastfeeding alongside the mother's clinical need. Given that postpartum is a time of elevated cardiovascular risk in women with prior events, the decision to hold or continue evolocumab during lactation should be made with your cardiologist and, ideally, a maternal-fetal medicine specialist.

Contraception Requirements

Women of reproductive age taking evolocumab should use reliable contraception, not because the drug is a known teratogen but because cardiovascular risk management during pregnancy requires a completely different medication regimen and unplanned pregnancy on a PCSK9 inhibitor requires prompt medication review.

Who This Is Right For and Who Should Pause

Women Who Are Strong Candidates

• Postmenopausal women with a documented ASCVD event (prior MI, stroke, or peripheral arterial disease) and LDL-C at or above 70 mg/dL on maximally tolerated statin therapy
• Women with familial hypercholesterolemia plus ASCVD
• Women with statin intolerance (documented myopathy or transaminase elevation) who cannot reach LDL goal on low-intensity statin or statin alternatives alone
• Women with PCOS and established ASCVD whose LDL-C remains above target
• Women with a history of premature atherosclerotic events, defined as MI or stroke before age 65

A practical framework for women pursuing Repatha coverage: Start with LDL documentation on maximally tolerated statin plus ezetimibe. If LDL remains at or above 70 mg/dL and you have established ASCVD with at least one additional high-risk feature (premature menopause, PCOS, diabetes, chronic kidney disease, or prior multiple events), you meet the threshold in current ACC/AHA guidelines where PCSK9 inhibitor addition earns a Class IIa recommendation. Build your PA letter around this exact framework using those ICD-10 codes and guideline language.

Women Who Should Pause or Proceed Carefully

• Women who are pregnant or planning pregnancy within 6-12 months
• Women who are breastfeeding (discuss benefit-risk with your provider)
• Women with LDL-C below 70 mg/dL on current therapy (the clinical benefit is less clear and insurance denial is near-certain)
• Women who have not yet tried high-intensity statin therapy at any dose (starting with a PCSK9 inhibitor before trying statin escalation is not guideline-supported and will be denied)

Biosimilars: The Cost-Relief Coming to Women on Repatha

Two evolocumab biosimilars are now FDA-approved: Amdrevall (evolocumab-kjmj, Sandoz) and a second product in the pipeline. FDA biosimilar approval data confirm interchangeability designations are in progress. Biosimilars typically enter the market at a 15-35% discount to the reference product's list price, which may meaningfully reduce the prior authorization pressure that currently exists because of cost. Women who are denied Repatha purely on cost grounds may find biosimilar entry the most practical path to affordable PCSK9 inhibition. Ask your pharmacy about availability in your state, as formulary placement varies significantly in the first 12-24 months after biosimilar launch.

What to Do If Your Insurer Keeps Saying No

A repeated denial is not the end. Concrete next steps:

1. Request the full denial letter with the specific criteria your claim failed to meet.
2. Ask your cardiologist to schedule a peer-to-peer review within 10 business days of denial.
3. File a formal first-level appeal with the FOURIER trial citation, FOURIER-OLE data, and the relevant ACC/AHA 2022 guideline section (Table 5, Very High Risk criteria).
4. If two appeals fail, request an external independent review under your state's insurance commissioner rules. Most states require this option.
5. While appealing, apply for Amgen's copay card or Safety Net Foundation to access medication during the appeals process if commercially insured.
6. Ask your cardiologist whether an evolocumab biosimilar is on a preferred tier for your plan; sometimes the biosimilar clears PA requirements more easily because of cost.
7. Contact your state insurance commissioner if the insurer violates timelines (most states require a PA decision within 72 hours for urgent requests and 14 days for standard requests).

The American Heart Association's 2021 policy statement on PCSK9 inhibitor access explicitly states that prior authorization barriers for guideline-indicated PCSK9 inhibitor therapy are a patient safety concern. That statement, cited in an appeal letter, carries weight.